Abstract -Numerous neurotransmitter systems [e.g. dopamine, y-aminobutyric acid (GABA), the endogenous opioids, and serotonin (5-hydroxytryptamine, 5-HT)] are involved in the regulation of alcohol consumption. Because 5-HT reuptalce inhibitors and opioid antagonists modify the activity of neurotransmitters, it has been hypothesized that they may also mediate the desire to drink alcohol by acting on specific receptors in the brain. Animal studies have shown that concomitant administration of 5-HT and opioid antagonists reduces alcohol consumption; therefore, the combined use of several pharmacotherapies may be the most effective treatment for alcohol dependence.
INTRODUCTION
To date, most pharmacologic approaches to the treatment of alcohol dependence have focused on modifying the activity of specific neurotransmitter systems [e.g. dopamine, y-aminobutyric acid (GABA), the endogenous opioids, and serotonin (5-hydroxytryptamine, 5-HT)] that are thought to be involved in the regulation of alcohol consumption (Hunt, 1993) . Several studies (O'Malley et al., 1992; Volpicelli et al., 1992; Naranjo and Bremner, 1994) have been conducted to determine if 5-HT reuptake inhibitors, such as fluoxetine, and opioid antagonists, such as naltrexone, mediate the desire to drink alcohol. Results from such studies indicate that 5-HT reuptake inhibitors and opioid antagonists may be effective adjunct pharmacotherapies for alcohol dependence. They also demonstrate that animal studies can help to identify pharmacological agents that may be clinically helpful to humans.
The 5-HT reuptake inhibitors and opioid antagonists modify the general activity of their respective neurotransmitter systems in a non-specific manner in humans and animals (Portoghese et al., 1990; Sellers et al., 1992) . However, molecular and neurobiological studies have shown that the 5-HT and opioid systems are highly complex 'Author to whom correspondence should be addressed. (Khachaturiane/a/., 1985; Hoyeref al., 1994) . At least seven different types and numerous other subtypes of 5-HT receptors have been identified (Hoyere-fa/., 1994; Martin and Humphrey, 1994) . Each type and subtype of 5-HT receptor is involved in the regulation of a specific behavioural or physiological response. Similarly, the endogenous opioid system involves various ligands, opioid receptors, and opioid receptor subtypes that subserve different behavioural and biological functions (Khachaturian etal., 1985) . Several preclinical studies have attempted to identify the specific 5-HT receptors and opioid receptors that are involved in the regulation of alcohol intake (Froehlich et al., 1991; Sellers et al., 1992; Hyytia, 1993; Le et al., 1993) . The identification of such receptors will no doubt hasten the development of safe, effective pharmacotherapies for alcohol dependence. Sellers et al. (1992) and others (Naranjo and Bremner, 1992) recently reviewed data on the use of 5-HT reuptake inhibitors in the treatment of alcohol dependence. Likewise, this article reviews preclinical studies of pharmaceutical agents that may regulate alcohol consumption by acting on 5-HT receptors and opioid receptors in the brain. It also addresses the possible use of concomitant medications in the treatment of alcohol dependence.
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5-HT RECEPTOR TYPES AND THEIR ROLE IN ALCOHOL CONSUMPTION
Pharmacological studies undertaken to identify the 5-HT receptor types and/or subtypes involved in the regulation of alcohol intake have concentrated mainly on the role of 5-HT 1A , 5-HT 2 and 5-HT 3 receptors for a variety of reasons, including their involvement in anxiolytic effects, their possible involvement in the rewarding effects of alcohol, and the availability of selective agonists and/or antagonists at these receptors.
5-HT IA receptors
Histological, biochemical, and behavioural evidence suggests that the 5-HT 1A receptors are involved in the regulation of alcohol intake. In studies conducted by McBride et al. (1990 McBride et al. ( , 1994 , rats that were selectively bred to have a high preference for alcohol, i.e. alcohol-preferring (P) and high alcohol-drinking (HAD) rats, had a greater number of 5-HT 1A binding sites in many areas of the brain than rats that were bred to have a low preference for alcohol, i.e. low alcoholdrinking (LAD) rats. It has been suggested that the P and HAD rats may have been predisposed to excessive volitional alcohol consumption because they had a greater number of 5-HT 1A binding sites. Furthermore, other studies have shown that the administration of 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), a 5-HT 1A agonist, reduces alcohol intake in rats (Kostowski and Dyr, 1992; Schreiber et al., 1993; Svensson et al., 1993) .
However, such observations are difficult to interpret for several reasons. First, the high doses of 8-OH-DPAT (>250/*g) administered in the studies may have elicited the '5-HT syndrome', which has deleterious effects on motor activity and interferes with consummatory behaviours (Smith and Peroutka, 1986) . Second, because high doses of 8-OH-DPAT affect autoreceptors and postsynaptic 5-HT 1A receptors in the brain, it is difficult to determine if the activation of postsynaptic 5-HT ]A receptors, or a combination of postsynaptic 5-HT 1A receptor activation and inhibition of 5-HT transmission, caused the observed effects.
In studies performed by Tomkins et al. (1994a, b) , selective activation of 5-HT 1A receptors in the raphe, either by peripheral administration of low doses of 8-OH-DPAT or by direct administration of 8-OH-DPAT into the median or dorsal raphe nucleus, stimulated alcohol intake in male Wistar rats. These authors concluded that alcohol intake was stimulated by selective activation of 5-HT 1A autoreceptors in the raphe, which, in turn, inhibited the transmission of 5-HT (Bendotti and Samanin, 1986; Hutson et al., 1986) .
However, it has yet to be established whether postsynaptic 5-HT 1A receptor subtypes are involved in the regulation of alcohol intake. 5-HT )A plays a complex role in autoregulation, and direct administration of 5-HT 1A agonists or antagonists into various areas of the brain, such as the hippocampus or nucleus accumbens (Stefanski et al., 1993) , may alter neurological functioning in those areas.
5-HT 2 receptors
Ritanserin, a 5-HT 2 receptor antagonist, has been reported to decrease (Meert et al., 1991; Meert, 1993; Panocka et al., 1993) or have no effect Myers and Lankford, 1993; Buczek et al., 1994) on consumption in rodents. Similarly, l-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and m-chlorophenylpiperazine hydrochloride (m-CPP), which are both 5-HT receptor agonists, have also been reported to decrease alcohol intake Buczek et al., 1994) .
Because such inconsistencies have been reported in the scientific literature, it is difficult to determine what role 5-HT 2 receptors play in alcohol intake. In addition, none of the pharmacological agents used in the aforementioned studies targets a specific 5-HT receptor subtype. For example, ritanserin is an antagonist for the 5-HT^ and 5-HT lc receptors, and m-CPP is an agonist for the 5-HT 1B and 5-HT 2C receptors (Hoyer et al., 1994) . Therefore, additional research is needed to match specific pharmacological agents to specific receptors.
5-HT 3 receptors
It probably can be said that the 5-HT 3 receptor has been the most studied of all the 5-HT receptors with regard to its underlying mechanisms and the role it plays in alcohol consumption. A variety of 5-HT 3 receptor antagonists, including ICS 205-930, MDL 72222, ondansetron and zacropride, have been shown to reduce alcohol consumption in rodents (Fadda et al., 1991; Knapp and Pohorecky, 1992; Hodge et al., 1993; Kos-towski et al., 1993; Tomkins et al., 1995) while leaving food intake unaffected . Such effects demonstrate one of the major differences between serotoninergic manipulation by 5-HT 3 receptor antagonists and other forms of serotoninergic manipulation in which alcohol intake is reduced by enhancing 5-HT function in the central nervous system. Both the 5-HT 3 receptor antagonists and other serotoninergic manipulators reduce alcohol-drinking behaviour by different, yet selective, mechanisms.
In some studies, subchronic administration of 5-HT 3 receptor antagonists (daily administration of 0.001 to 0.1 mg/kg for 3 to 6 days) produces few side-effects. In addition, in such studies, tolerance to the alcohol-intake-reducing effects of the 5-HT 3 receptor antagonists was minimal (Tomkins et al., 1995) . In a study of human subjects (Johnson et al., 1993) , ondansetron hydrochloride, a 5-HT 3 receptor antagonist, reduced some of the mood-altering effects of alcohol. In addition, in another study by Sellers et al. (1994) , ondansetron reduced alcohol intake in human alcohol-dependent subjects. Such findings support the use of 5-HT 3 receptor antagonists in the treatment of alcohol dependence.
OPIOID ANTAGONISTS
Numerous studies have shown that alcohol consumption can also be modified by activation or blockade of the endogenous opioid system (for review, see Reid and Hubbell, 1990) . Animal and human studies have shown that treatment with opioid antagonists, such as naloxone (Reid and Hunter, 1984; Hyytia and Sinclair, 1993) and naltrexone (Linseman, 1989; Volpicelli et al., 1992; O'Malley etal., 1992; Le etal., 1993) , can reduce alcohol consumption. At this time, naltrexone, which was recently approved for use by the US Food and Drug Administration, appears to be the most promising adjunctive pharmacotherapy for alcohol dependence.
Although naltrexone and naloxone have a high affinity for mu-opioid receptors, they also block delta-and kappa-opioid receptors (Portoghese et al., 1990) . To our knowledge, only three studies published in the scientific literature have examined the relationship between specific opioid receptors and alcohol intake. First, Froehlich et al. (1991) have reported that selective blockade of delta-opioid receptors reduces alcohol consumption in alcohol-preferring rats. Second, Le et al. (1993) have reported that selective blockade of delta-opioid receptors (but not mu-opioid receptors) reduces alcohol intake in C57BL/6 mice. Third, Hyytia (1993) has reported that blockade of mu-opioid receptors (but not deltaopioid receptors) reduces alcohol intake in Alkoalcohol (AA)-type rats that are selectively bred for high alcohol intake.
However, a receptor binding study (C. Gianoulakis, personal communication) has revealed that rats of the AA line have a very high density of mu-opioid binding sites and very few deltaopioid receptors throughout various limbic structures in the brain. In addition, Mason et al. (1994) have reported that the delta-opioid receptors play a role in alcohol consumption. In their study, alcohol-dependent subjects who were treated with nalmefene, an opioid antagonist with high affinity for delta-opioid receptors, consumed less alcohol than subjects who were treated with placebo.
INTERACTIONS AMONG NEUROTRANSMITTERS
As stated earlier, most pharmacological approaches to the treatment of alcohol dependence have focused on modifying the activity of a specific neurotransmitter system. However, it is now known that numerous neurotransmitter systems are involved in the regulation of alcohol consumption and that these systems interact in various ways to regulate behavioural and physiological functions (Imperato and Angelucci, 1989; Benj amin etal., 1993; Panocka et al., 1993) . For example, mesolimbic dopamine, which has been hypothesized to play a critical role in the rewarding properties of many drugs of abuse, has been found to be modulated by the opioid (Di Chiara and Imperato, 1988) and 5-HT systems (Imperato and Angelucci, 1989; Hjorth and Sharp, 1991; Yoshimoto and McBride, 1992) .
Several studies have examined the neurotransmitter systems that are involved in the modulation of alcohol intake (Fadda et al., 1991; Froehlich et al., 1991 Higgins et al., 1992 ; however, few have systematically investigated the interactions that occur between such systems. Therefore, we recently conducted a study to determine whether the opioid and 5-HT systems interact to regulate alcohol intake in C57BL/6 mice and Wistar rats (Le and Sellers, 19%) . Specifically, we looked for an interaction between naltrexone (an opioid antagonist) and ondansetron hydrochloride (a 5-HT 3 receptor antagonist). We chose to study these two agents because it has been reported that ondansetron and naloxone, another narcotic antagonist, interact synergistically in suppressing food intake in mice (Beczkowska and Bodnar, 1991) . Naltrexone and ondansetron have also been shown to block alcohol-stimulated, non-spontaneous dopamine release in the nucleus accumbens of the rat (Wozniak et al., 1990; Benjamin et al., 1993) .
In our study of mice and rats, alcohol intake was not affected when naltrexone and ondansetron were administered individually and in low dosages (Le and Sellers, 1996) . However, when naltrexone (0.075 mg/kg/day) and ondansetron (0.001 mg/kg/day) were administered concomitantly, the mice and rats exhibited a marked reduction in alcohol intake, but no change in water consumption. Since it has been reported that naltrexone and ondansetron may be effective monotherapies for alcohol dependence (Volpicelli et al., 1992; O'Malley et al., 1992; Sellers et al., 1994) , the finding that they also have a strong synergistic effect is of clinical importance.
CONCLUSIONS AND COMMENTS
Litten and Allen (1991) have reviewed a number of promising pharmacotherapies for alcohol dependence and have identified several clinical issues that may affect future research. They point out that pharmacological agents for alcohol dependence should be equally effective at reducing alcohol intake, producing few side-effects, and promoting patient compliance. Without a doubt, future studies of the neurotransmitter systems that are involved in the regulation of alcohol intake will also address such issues.
In addition, many processes, such as sensitivity to the rewarding properties of alcohol, craving, and loss of control, are involved in the initiation and maintenance of excessive alcohol intake. It is likely that the neurobiological mechanisms that mediate such processes are also numerous. Therefore, the combined use of several pharmacotherapies may be the most effective treatment for alcohol dependence.
